The Spanish biotech company Biohope has secured a €2 million grant from the Comunidad de Madrid to advance its innovative diagnostic device, MTX-CELL. This tool predicts the efficacy of Methotrexate (MTX) in patients with Rheumatoid Arthritis (RA), enabling personalized treatment from the outset. By optimizing therapy, MTX-CELL reduces costs associated with ineffective treatments and improves patient outcomes.

This achievement was made possible with the support of Aristos by PNO, whose expertise contributed to Biohope obtaining the prestigious Seal of Excellence from the European Innovation Council (EIC) Accelerator program. The Seal of Excellence recognizes high-potential projects of exceptional quality and relevance, even if they do not receive direct EU funding.